Lenalidomid Olainfarm

Lenalidomide, the active ingredient in Lenalidomid Olainfarm, is an immunomodulatory imide drug (IMiD) presented as a tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomid Olainfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with distribution across EU and other regulated markets. The product complies with EU GMP requirements and is manufactured under strict quality controls.

Lenalidomide is employed in the management of several hematologic malignancies and related bone‑marrow disorders, where it modifies disease biology and improves clinical outcomes. - Multiple myeloma: improves progression‑free survival and overall response in adult patients. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission. - Mantle cell lymphoma: used in combination regimens to achieve disease control in relapsed or refractory cases. - Transfusion‑dependent anemia in del(5q) MDS: helps achieve transfusion independence and improves blood counts. - Relapsed or refractory disease: provides an additional therapeutic option when standard regimens have failed.

Common Side Effects: - Fatigue. - Neutropenia. - Constipation.

Serious or Rare Side Effects: - Venous thromboembolism. - Severe liver enzyme elevation. - Secondary primary malignancies.

Before initiating therapy, consider the following precautions: - Pregnancy: contraindicated (Category X) – avoid use in pregnant women. - Thrombosis risk: assess and manage risk factors prior to treatment. - Renal impairment: monitor renal function and adjust follow‑up as needed. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Drug interactions: avoid concomitant use with strong CYP inducers without medical supervision. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lenalidomid Olainfarm may interact with several medicines. Review the following: Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: risk of infection due to immunomodulation. Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin): may increase bleeding risk. - Other immunomodulatory agents (e.g., thalidomide): additive toxicity. - Hepatotoxic drugs (e.g., azole antifungals): may increase liver toxicity.